AIDX earnings: next report 2026-09-02, real EPS beat/miss history, P/E -0.95. Updated 2026-07-23.
20/20 Biolabs (AIDX) Research Hub
20/20 Biolabs (AIDX) trades on NASDAQ, US in the Healthcare (Medical - Care Facilities) sector. As of 2026-09-11, shares last closed at 0.56 USD (-0.81%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.95, market cap 0.00B. This hub links to the full technical, earnings and options research available for AIDX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Medical - Care Facilities) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 0.56 USD (-0.81%) |
| 52-week range | 0.4011 USD – 0.7893 USD |
| Trend regime | Range |
| 14-day RSI | 62.8 (Bullish) |
| Trailing P/E | -0.95 |
| Market cap | 0.00B |
| Dividend yield | 0.00% |
| Next earnings | 2026-09-02 |
Available research for AIDX
Covered Call on AIDX: how it works, illustrative setup around the real 0.56 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on AIDX: how it works, illustrative setup around the real 0.56 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on AIDX: how it works, illustrative setup around the real 0.56 USD price, max profit/loss, breakeven and when to use it. Educational.
AIDX technical analysis: range, last 0.56 USD, RSI 62.8, 52w range 0.4011 USD–0.7893 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is AIDX in?
20/20 Biolabs (AIDX) is classified under Healthcare (Medical - Care Facilities), listed on NASDAQ, US.
Is AIDX in an uptrend or downtrend?
As of 2026-09-11, AIDX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is AIDX's trailing P/E ratio?
AIDX's trailing P/E is -0.95, with a market cap of 0.00B. See the earnings research page for full valuation detail.
When does AIDX next report earnings?
AIDX is next scheduled to report earnings on 2026-09-02, with a consensus EPS estimate of -0.12 USD.